ARS Pharmaceuticals (SPRY) Current Leases (2020 - 2025)

ARS Pharmaceuticals has reported Current Leases for 6 years, with the latest figure at $583000.0 in Q3 2025.

• Quarterly Current Leases rose 471.57% year-over-year to $583000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $583000.0 (up 471.57% YoY) and the FY2024 annual result came in at $42000.0, down 82.28% from the prior year.
• Current Leases fell to $583000.0 in Q3 2025 per SPRY's latest filing, from $589000.0 in the prior quarter.
• Over five years, Current Leases peaked at $1.1 million in Q1 2022 and troughed at $42000.0 in Q4 2024.
• A 5-year average of $435315.8 and a median of $233000.0 in 2023 frame the typical range for Current Leases.
• The sharpest annual moves came in 2021 and 2025: Current Leases sank 83.93% in 2021, then soared 471.57% in 2025.
• Over 5 years, Current Leases stood at $144000.0 in 2021, then soared by 59.72% to $230000.0 in 2022, then climbed by 3.04% to $237000.0 in 2023, then tumbled by 82.28% to $42000.0 in 2024, then surged by 1288.1% to $583000.0 in 2025.
• According to Business Quant data, Current Leases over the past three periods registered $583000.0, $589000.0, and $73000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.